Witten/Herdecke University at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Witten/Herdecke University brings 6 presentations to ESGCT 2026 in Hamburg. Its work centres on adenoviral vectors, from next-generation designs for better delivery to chimeric helper-dependent vectors for a bleeding disorder. Other strands develop oncolytic adenoviruses against pancreatic and head and neck cancers, with patient-derived models to test them.
| Organization | ESGCT 2026 Attendance |
|---|---|
Witten/Herdecke University Witten, Germany | |
Private German university whose groups study adenoviral vectors for gene therapy. | Workshop Tue Oct 27 9:55am–10:45am The Science of Adenoviral Vectors: How Do They Work and Why Do They Matter? Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 8:30am–10:30am Engineering next-generation adenoviral vectors for improved delivery: new strategies and emerging opportunities Vectors and delivery (AAV, lentiviral, LNP) Chair Wed Oct 28 8:30am–10:30am SESSION 3c: Oncolytic therapy & cancer gene therapy Cancer gene and cell therapy Poster Wed Oct 28 1:30pm–3:30pm Generation and characterization of novel oncolytic adenoviruses for treatment of pancreatic ductal adenocarcinoma Poster Wed Oct 28 1:30pm–3:30pm Selection and Rational Design of Chimeric Helper-Dependent Adenoviral Vectors for Type 3 von Willebrand Disease (VWD) Poster Thu Oct 29 2:00pm–4:00pm Effects of adenoviral death protein in oncolytic adenoviruses under transcriptional control of the human telomerase reverse transcriptase promoter Poster Thu Oct 29 2:00pm–4:00pm Patient derived in vitro models for head and neck squamous cell carcinoma (HNSCC) reveal alternative Adenovirus types as prototypes for the development of improved virotherapies Cancer gene and cell therapy |
Instantly find 20 buyers from Witten/Herdecke University
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction